Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment

  • STATUS
    Recruiting
  • participants needed
    150
  • sponsor
    University Hospital, Brest
Send
Updated on 16 February 2024
See if I qualify
rheumatic diseases
DMARD
corticosteroids
anti-rheumatic drugs
steroidal anti-inflammatory drugs
arthritis
covid-19
SARS
disease modifying antirheumatic drugs
antirheumatic
acute respiratory syndrome (sars)

Summary

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.

Details
Condition Therapeutic procedure, JUVENILE RHEUMATOID ARTHRITIS, treatment, Arthritis, Covid 19
Age 17years or below
Clinical Study IdentifierNCT04407923
SponsorUniversity Hospital, Brest
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Juvenile Idiopathic Arthritis satisfying Edmonton criteria
Ongoing DMARD therapy or AINS for 3 months

Exclusion Criteria

Inhability to consent
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

rheumatic diseases
DMARD
corticosteroids
anti-rheumatic drugs
steroidal anti-inflammatory drugs
arthritis
covid-19
SARS
disease modifying antirheumatic drugs
antirheumatic
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.